Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream used for treating plaque psoriasis and atopic dermatitis. The company is also developing ZORYVE foam for seborrheic dermatitis and scalp and body psoriasis, as well as ARQ-234, a fusion protein that acts as a potent and highly selective checkpoint agonist of the CD200 receptor. Arcutis aims to address unmet medical needs in dermatology by leveraging its expertise in topical therapies.

Arcutis Biotherapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ARQT. Its shares are traded in US Dollars (USD), as the company is headquartered in the United States. The NasdaqGS is a major US stock exchange known for listing many healthcare and technology companies, providing liquidity and visibility for Arcutis among investors.

Arcutis Biotherapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of innovative therapies, particularly for dermatological conditions. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and potential for breakthrough treatments, which aligns with Arcutis's mission to develop topical treatments for skin diseases.

Arcutis Biotherapeutics is headquartered in Westlake Village, California, United States. The company was incorporated in 2016 and was formerly known as Arcutis, Inc. before rebranding to its current name in October 2019. Its operations are primarily based in the US, focusing on the domestic market for its dermatological products. The company's location in California places it within a major biotech hub, providing access to talent and resources.

Arcutis Biotherapeutics' main product is ZORYVE, a topical roflumilast cream approved for plaque psoriasis and atopic dermatitis. The company is also developing ZORYVE foam for seborrheic dermatitis and scalp and body psoriasis. Additionally, Arcutis is working on ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor, which represents a novel approach in dermatology. These products target common skin conditions with significant patient populations.